When to Stop Atropine in Organophosphate Poisoning
Stop atropine when full atropinization is achieved, defined by clear chest on auscultation, heart rate >80/min, and systolic blood pressure >80 mm Hg, then maintain this state with continuous atropine infusion rather than abruptly discontinuing. 1
Atropinization Endpoints (When to Stop Escalating Doses)
The 2023 American Heart Association guidelines provide clear, objective criteria for when adequate atropinization has been reached 1:
- Clear chest on auscultation (no bronchorrhea/secretions)
- Heart rate >80 beats per minute
- Systolic blood pressure >80 mm Hg
Dosing Algorithm Until Atropinization
Start with an initial dose of 2-3 mg IV (much higher than typical bradycardia dosing), then double the dose every 5 minutes until the above endpoints are met 1. This is a Class I, Level A recommendation—the strongest evidence level available.
Key Distinction from Typical Bradycardia Treatment
The FDA label and ACC/AHA bradycardia guidelines recommend only 0.5-1 mg for typical bradycardia 2, 3, but organophosphate poisoning requires dramatically higher doses—often 20-75 mg or more to achieve initial control 4, 5. One case report documented successful treatment requiring 11.6 grams over 12 days 4, and another required 102 mg/hour infusion 6.
Maintenance Phase (After Initial Atropinization)
Do not abruptly stop atropine once atropinization is achieved. Instead:
- Transition to continuous atropine infusion to maintain atropinization 1
- Continue monitoring for recurrence of cholinergic signs
- Duration may extend for days to weeks depending on the specific organophosphate 6, 7
Critical Pitfall: Premature Discontinuation
Evidence shows that stopping atropine or oximes too early (after 1-2 days) leads to relapse of cholinergic symptoms 7. One case demonstrated relapse when oximes were stopped after one day, but no relapse when continued for six days 7. Similarly, severe cases may require atropine for 60 days or longer 6.
When to Actually Discontinue Atropine
Gradually wean atropine when:
- No recurrence of cholinergic signs for an extended period (typically days)
- Organophosphate has been eliminated (varies by compound—some have prolonged absorption or lipid redistribution)
- Acetylcholinesterase activity is recovering (if monitoring available)
- Patient remains stable during dose reduction
The specific timeline depends on:
- Type of organophosphate (lipophilic compounds redistribute from fat stores)
- Route of exposure (dermal absorption continues for hours)
- Whether "aging" has occurred (permanent enzyme inactivation requiring new enzyme synthesis)
Monitoring During Weaning
Watch for return of:
- Bronchorrhea/bronchospasm
- Bradycardia
- Miosis
- Fasciculations
- Altered mental status
If any cholinergic signs recur, immediately resume higher atropine doses—do not continue weaning 7.
Important Caveats
Atropine only treats muscarinic effects—it does not reverse nicotinic effects (paralysis, fasciculations) or CNS effects completely 1, 3. This is why pralidoxime (oxime) is also recommended and should be continued for similar extended periods 7.
Atropine toxicity is rare in this context because the massive cholinergic excess from organophosphates antagonizes atropine's effects 4, 6. The usual atropine side effects (tachycardia, mydriasis, urinary retention) are actually therapeutic goals in severe poisoning.
Human case reports demonstrate that extremely high doses (up to 102 mg/hour) can be safely administered when clinically indicated 6, far exceeding typical maximum doses, because the organophosphate poisoning creates a unique pharmacologic situation where standard dosing limits do not apply.